Dantrolene

USDailyMed:Dantrolene AU:B2 M03CA01(WHO) CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 1-{[5-(4-nitrophenyl)-2-furyl]methylideneamino}imidazolidine-2,4-dione 7261-97-4Y 2952 4172 DB01219Y 2847Y F64QU97QCR D02347N CHEBI:4317Y ChEMBL1201288N DTXSID7022881 Interactive image [O-][N+](=O)c3ccc(c2oc(C=NN1C(=O)NC(=O)C1)cc2)cc3 InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)YKey:OZOMQRBLCMDCEG-UHFFFAOYSA-NY Dantrolene sodium, sold under the brand nameDantriumamong others, is a postsynapticmuscle relaxantthat lessensexcitation-contraction couplinginmuscle cells.It achieves this by inhibitingCa2+ionsrelease fromsarcoplasmic reticulumstores by antagonizingryanodine receptors.It is the primary drug used for the treatment and prevention ofmalignant hyperthermia, a rare, life-threatening disorder triggered bygeneral anesthesiaordrugs. It is also used in the management ofneuroleptic malignant syndrome, musclespasticity(e.g. afterstrokes, inparaplegia,cerebral palsy, or patients withmultiple sclerosis), and poisoning by2,4-dinitrophenolor by the related compoundsdinosebanddinoterb. The most frequently occurring side effects include drowsiness, dizziness, weakness, general malaise, fatigue, and diarrhea. It is marketed by Par Pharmaceuticals LLC as Dantrium (in North America) and by Norgine BV as Dantrium, Dantamacrin, or Dantrolen (in Europe). A hospital is recommended to keep a minimum stock of 36 dantrolene vials totaling 720 mg, sufficient for a 70-kg person.